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Abstract: Small nucleolar RNAs (snoRNAs) are a new type of functional small RNAs involved in
the chemical modifications of rRNAs, tRNAs, and small nuclear RNAs. It is reported that they play
important roles in tumorigenesis via various regulatory modes. snoRNAs can both participate in the
regulation of methylation and pseudouridylation and regulate the expression pattern of their host
genes. This research investigated the expression pattern of snoRNAs in eight major cancer types in
TCGA via several machine learning algorithms. The expression levels of snoRNAs were first analyzed
by a powerful feature selection method, Monte Carlo feature selection (MCFS). A feature list and some
informative features were accessed. Then, the incremental feature selection (IFS) was applied to the
feature list to extract optimal features/snoRNAs, which can make the support vector machine (SVM)
yield best performance. The discriminative snoRNAs included HBII-52-14, HBII-336, SNORD123,
HBII-85-29, HBII-420, U3, HBI-43, SNORD116, SNORA73B, SCARNA4, HBII-85-20, etc., on which the
SVM can provide a Matthew’s correlation coefficient (MCC) of 0.881 for predicting these eight cancer
types. On the other hand, the informative features were fed into the Johnson reducer and repeated
incremental pruning to produce error reduction (RIPPER) algorithms to generate classification rules,
which can clearly show different snoRNAs expression patterns in different cancer types. The analysis
results indicated that extracted discriminative snoRNAs can be important for identifying cancer
samples in different types and the expression pattern of snoRNAs in different cancer types can be
partly uncovered by quantitative recognition rules.
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1. Introduction
Small nucleolar RNAs (snoRNAs) are a group of functional small RNAs that mainly participate
in the chemical modifications of other functional RNAs, such as rRNAs, tRNAs, and small nuclear
RNAs [1–3]. Generally, snoRNAs may participate in two major biological functions, namely, 2′-O-ribose
methylation and pseudouridylation of pre-rRNAs [4,5]. snoRNAs interact with at least four protein
molecules; thus, snoRNAs form a complicated RNA/protein complex for further modification
processes [6,7]. For the detailed recognition on the functional RNA molecules, snoRNAs has a
specific antisense nucleotide element containing 10–20 nucleotides that complementary pair with the
targeted pre-RNA molecules [8]. After the precise identification and localization processes mediated
by this antisense element, the four interacted protein molecules around snoRNAs are located at the
correct physical position and contribute to the chemical modification of the target bases [7].
The basic biological processes of snoRNAs are relatively similar based on the objective modification
pattern of pre-rRNAs; thus, snoRNAs can be classified into two major subtypes, namely, C/D and
H/ACA boxes [9,10]. The C/D box snoRNAs have two major boxes, namely, C (RUGAUGA, R=purine)
and D (CUGA), playing different biological roles during the modification targets of our snoRNPs [11].
They guide the position-specific 2′-O-methylation and are associated with the four evolutionarily
conserved proteins, fibrillarin (methyltransferase), NOP56/NOL5A, NOP5/NOP58, and NHP2L1, which
constitute the core of C/D snoRNPs. These motifs of snoRNAs and related RNPs are mainly involved
in the methylation regulation of the targeted pre-rRNAs. According to recent publications [11,12],
the direct methylation modification sites of C/D snoRNAs are located precisely 5 bp upstream of the D
box of snoRNPs, reflecting the accurate positioning and effective regulatory contribution of snoRNAs.
Different from C/D snoRNAs, H/ACA box snoRNAs have two specific hairpins and two short
single-stranded regions (H and ACA boxes), from which its cluster name was derived [13]. H/ACA
snoRNAs direct RNA pseudouridylation of rRNA and are associated with dyskerin (pseudouridine
synthase), GAR1, NHP2, and NOP10. Similar to D box in the C/D box snoRNP complexes, H and
ACA boxes also do not only participate in the pseudouridylation modification of pre-rRNAs but more
critically contribute to the precise recognition of the target uridylation sites of pre-rRNAs [14]. With the
development of biological technologies and related studies, some novel snoRNA subgroups, such as
composite H/ACA and C/D boxes and orphan snoRNAs, with relatively different biological functions
have been constantly identified [15,16]. However, these groups of snoRNAs either have similar
function pattern (e.g., composite H/ACA and C/D boxes), with general groups or have no validated
experimental evidence on their specific biological functions (e.g., orphan snoRNAs). Therefore, on the
basis of the existing literature, researchers conclude that snoRNAs with different functional subgroups
mainly participate in the regulation of pre-rRNA methylation and pseudouridylation.
As a subgroup of noncoding RNAs, snoRNAs was also recently confirmed to involve in
tumorigenesis in various regulatory modes as reported in recent publications [17–20]. First, snoRNAs
participate in the regulation of methylation and pseudouridylation. Early studies confirmed that
some biological components of snoRNPs, such as SNORA42 and U50, may have specific expression
pattern or directly participate in tumorigenesis, indicating that snoRNPs may be functionally related to
cancer [20,21]. Second, snoRNAs may also be functionally connected to cancer through its host genes.
A recent study on Zfas1 on a tumor-associated nonprotein-coding snoRNA host gene confirmed that
three C/D box snoRNAs might regulate the expression of their host gene Zfas1, and further indirectly
mediate tumorigenesis [22]. Furthermore, a study on another gene named GAS5 confirmed that
snoRNAs (C/D box) encoded by its own intron may contribute to the progression of tumorigenesis
similar to its host gene, GAS5 [23]. Although confirmation is still needed on the topic of whether
the snoRNA functions are independent of their respective host genes, both snoRNAs and the host
genes may promote tumorigenesis in a cooperative and synergetic pattern, implying the complicated
contribution of snoRNAs on tumorigenesis.
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Thus, as we have analyzed above, snoRNAs have been confirmed to contribute to the tumorigenesis
in their specific ways. On the other hand, several studies have been reported that miRNAs/lncRNAs
are highly related to different diseases [24–28], including tumor, which gives a strong hint for the
associations between snoRNAs and different tumors. The analysis of the expression pattern on them is
an essential way. This study gave a computational investigation of the snoRNA expression pattern of
different tumors. Recently, a systematic study [29] on the distribution of different snoRNAs in different
tumor subtypes based on TCGA database has been presented, drawing a detailed blueprint of snoRNAs
during tumorigenesis. According to the dataset provided by such study, we firstly screened out the
specific expression pattern of snoRNAs in eight candidate tumor subtypes. Then, based on some
powerful machine learning algorithms, we tried to screen out the core distinctive distributed snoRNAs
among such eight candidate cancer subgroups and further established a qualitative snoRNA-based
recognition standard for further tumor subtyping.
2. Results
2.1. Results of MCFS Method
In this study, we used the Monte Carlo feature selection (MCFS) to analysis expression levels of
1524 snoRNAs. Each feature was assigned a relative importance (RI) score and all features were ranked
in descending order based on their RI scores. The obtained feature list is listed in Table S1.
Furthermore, the MCFS method can generate some informative features. Here, 411 features were
produced for the problem addressed in this study. Based on them, 69 classification rules were produced
by the Johnson reducer algorithm and the repeated incremental pruning to produce error reduction
(RIPPER) algorithm, which are listed in Table S2. To evaluate the performance of the rules yielded
by the above two algorithms, 10-fold cross-validation was performed thrice, yielding the predicted
accuracy of 0.750 and weighted accuracy of 0.751. The true positive rates (TPRs) and false positive rates
(FPRs) of the individual classes are shown in Table 1. The confusion map is illustrated in Figure 1A.
Table 1. Results of 10-fold cross-validation by using 69 produced classification rules and the optimal
support vector machine (SVM) classifier.
Cancer Type Classification Rules Optimal SVM Classifier
TPR † FPR ‡ TPR † FPR ‡
HNSC 0.683 0.040 0.877 0.023
KIRC 0.815 0.046 0.927 0.003
LGG 0.928 0.012 0.979 0.003
LUAD 0.550 0.051 0.839 0.034
LUSC 0.595 0.047 0.731 0.023
PRAD 0.868 0.019 0.978 0.023
THCA 0.884 0.033 0.966 0.004
UCEC 0.684 0.038 0.869 0.006
† True positive rate, ‡ False positive rate.
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Figure 1. Confusion matrices for 10-fold cross-validation based on two classifiers. (A) The confusion 
matrix yielded by the 69 produced classification rules for classifying samples from 8 cancer types. The 
numbers were pooled by running 10-fold cross-validation on the training data thrice. (B) The 
confusion matrix yielded by the optimal support vector machine (SVM) classifier. The numbers were 
pooled by running 10-fold cross-validation on the training data once. 
2.2. Results of IFS with SVM 
We also used support vector machines (SVMs) to classify samples consisting of important 
features that were selected from the incremental feature selection (IFS) method. First, a set of feature 
subsets with a step 1 were constructed. After testing the performance of SVMs on the samples 
consisting of features from individual feature subsets with 10-fold cross-validation once, we obtained 
the highest Matthew’s correlation coefficient (MCC) of 0.881 when the top 443 snoRNAs were used. 
In addition, we can yield an MCC value of 0.708 when using only the top 72 features. The predicted 
accuracies for individual cancers, overall accuracies, and MCCs by using a different number of 
features are listed in Table S3. Furthermore, we presented the MCC trends corresponding to the 
number of features involved in building the SVM classifiers, as shown in Figure 2A, in which the 
optimal MCC value of 0.881 is marked with a red rhombus. Accordingly, we termed the SVM 
classifier using top 443 features as the optimal SVM classifier. The confusion matrix generated by the 
10-fold cross-validation on this classifier is illustrated in Figure 1B, from which we can see that the 
Figure 1. Confusion matrices for 10-fold cross-validation based on two classifiers. (A) The confusion
matrix yielded by the 69 produced classification rules for classifying samples from 8 cancer types.
The numbers were pooled by running 10-fold cross-validation on the training data thrice. (B) The
confusion matrix yielded by the optimal support vector machine (SVM) classifier. The numbers were
pooled by running 10-fold cross-validation on the training data once.
2.2. Results of IFS with SVM
We also used support vector machines (SVMs) to classify samples consisting of important features
that were selected from the incremental feature selection (IFS) method. First, a set of feature subsets
with a step 1 were constructed. After testing the performance of SVMs on the samples consisting of
features from individual feature subsets with 10-fold cross-validation once, we obtained the highest
Matthew’s correlation coefficient (MCC) of 0.881 when the top 443 snoRNAs were used. In addition,
we can yield an MCC value of 0.708 when using only the top 72 features. The predicted accuracies for
individual cancers, overall accuracies, and MCCs by using a different number of f atures ar listed
in T ble S3. Furthermore, we present d the MCC trends corr sponding to the number of features
involved in building the SVM classifiers, as shown in Figure 2A, in hich the optimal MCC valu of
0.881 s marked with a red rhombus. Accordingly, we termed the SVM classifier using top 443 features
as the optimal SVM classifier. The confusion matrix generated by the 10-fold cross-validation on this
classifier is illustrated in Figure 1B, from which we can see that the performance of the optimal SVM
classifier was much better than that of 69 classification rules. The TPRs and FPRs of the individual
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classes yielded by such a classifier are listed in Table 1. Compared with those yielded by classification
rules, the TPRs produced by the optimal SVM classifier were much higher and FPRs were lower
(except one), suggesting the optimal SVM classifier gave a much better performance. In addition, we
also counted the performance of the optimal SVM classifier on each of the ten folds. The highest and
lowest accuracies for each cancer type were listed in Table 2.
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Furthermore, we also used a 5-fold cross-validation to replace the 10-fold cross-validation in the 
above procedures. The MCC trends corresponding to the number of used features are shown in 
Figure 2B. The trends of MCC in the two curves were almost the same. The performance yielded by 
the 5-fold cross-validation was slightly lower than that obtained by the 10-fold cross-validation. It is 
reasonable because, in a 5-fold cross-validation, fewer samples were used to train the classifiers. 
Table 2. The lowest and highest accuracies for each cancer type yielded by the optimal SVM classifier 
on each of ten folds. 
Cancer Type Highest Accuracy Lowest Accuracy 
HNSC 0.930 0.807 
KIRC 0.949 0.897 
LGG 1.000 0.922 
LUAD 0.875 0.786 
LUSC 0.808 0.654 
PRAD 1.000 0.925 
THCA 1.000 0.931 
UCEC 0.930 0.789 
Figure 2. IFS curves derived fro the I t cla sifiers. The x-axi is the number of
features involved in building clas ifiers, - xis is their corresponding Matthew’s correlation
coefficient (MC ) values. (A) The IF c -fold cro s-validation. (B) The IFS curve
yielde by 5-fold cross-validation.
Furthermore, we als a 5-fold cross-validation to replac the 10-fold cross-validation in
the above procedures. The MCC trends corresponding o the number of used features are show in
Figure 2B. The trends of MCC in the t o c l st the same. The performance yiel ed by
the 5-fold cross-validation was slightly lo er t a t at tained by the 10-fold cross-validation. It is
reasonable because, in a 5-fold cross-validation, fe er sa ples ere used to train the classifiers.
Table 2. The lowest and highest accuracies for each cancer type yielded by the optimal SVM classifier
on each of ten folds.
Cancer Type Highest Accuracy Lowest Accuracy
HNSC 0.930 0.807
KIRC 0.949 0.897
LGG 1.000 0.922
LUAD 0.875 0.786
LUSC 0.808 0.654
PRAD 1.00 0.925
THCA 1.00 0.931
UCEC 0.930 0.789
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3. Discussion
On the basis of some machine learning methods, we identified not only a group of effective core
regulatory snoRNAs that may participate in tumorigenesis and contribute to the distinction of the eight
candidate tumor subtypes, but we also set up a series of qualitative rules for the precise recognition of
different subtypes according to the expression pattern of the optimal parameters. According to recent
publications, some obtained key distinctive snoRNAs and specific distinctive qualitative rules can be
verified, validating the reliability of our results.
As we have mentioned above, snoRNAs are a group of small nucleolar RNAs that generally
contribute to the regulation of RNA modifications. Ribosomal RNAs, transfer RNAs, and small
nuclear RNAs are the three subgroups of snoRNAs. SnoRNAs generally act as a guide for specific
modification on a target RNA in the form of RNA/protein complex together with multiple protein
molecules. Such complexes (also called small nucleolar ribonuceloproteins) further contribute to the
accurate chemical modification of a target RNA sequence. When analyzing the biological functions of
snoRNAs, we just screened out the targets of snoRNAs and tried to explain the biological effects of
these snoRNAs based regulatory roles on such targets, which may help explain the biological function
of snoRNAs. Comparing to snoRNAs, miRNAs/lncRNAs do not directly affect the chemical structure
and composition of mRNAs. Such RNAs regulate gene functions by affecting gene expression levels
directly or indirectly. Thus, when analyzing the biological functions of such two kinds of RNAs,
we analyzed the expression alteration effects of features in certain physical or pathological conditions.
Therefore, the analysis of miRNAs/lncRNAs and snoRNAs are quite different. In this study, we applied
the proper functional analysis on key distinctive snoRNAs and rules associated snoRNAs.
3.1. Analysis of Optimal Tumor-Associated snoRNAs
Based on the dataset provided by our reference and the newly applied computational approach,
we identified a group of functional snoRNAs that may have distinctive expression pattern in eight
tumor subtypes. Here, we presented a detailed analysis of a number of snoRNAs.
The first snoRNA is HBII-52-14, which is a C/D box snoRNA that was first cloned by Cavaill
in 2000 [30]. As a transcript that is specifically expressed in the brain, HBII-52-14 may target the
serotonin receptor (5HT-2C) in the brain, and regulate its functional methylation status [30,31]. Recent
publications confirmed that the expression pattern of 5HT-2C, regulated by our identified snoRNA,
is pathogenic and may be involved in the initiation and progression of low-grade glioma (LGG) [32].
This result implies that this parameter may be effective in differentiating glioma from other tumor
subtypes. HBII-52-10, HBII-52-15, HBII-52-32, HBII-52-5, and HBII-52-4 have also been confirmed to
target serotonin, connecting this regulatory function to the potential glioma tumorigenesis.
In addition to this series of snoRNAs, HBII-336 (with a rank of 3 in the feature list, yielded by the
MCFS method) is also validated to contribute to the distinction of different tumor subtypes by recent
publications. First described by Huttenhofer in 2001 [33], HBII-336 guides the 2′-O-ribose methylation
of 18S rRNA A576 [33]. Recent publications also confirmed that the methylation of 18S rRNA may
be functionally related to the initiation and progression of certain tumor subtypes, such as breast
cancer, colorectal cancer, and renal carcinoma [34,35]. Comparing these findings with those results
for the eight tumor subtypes investigated in this study, the expression of HBII-336 can be helpful for
tumor subtyping.
HBI-43, as another identified snoRNA has also been confirmed to participate in the distinction of
different cancer subtypes. According to recent publications, such snoRNA has been functionally related
to a specific effective gene TRIM25 [36]. Such a gene has been identified to have pathogenic expression
pattern in breast cancer [37] and hepatocellular carcinoma [38]. Therefore, it is quite reasonable to
speculate that as the regulator of TRIM25, the expression pattern of HBI-43 may also be sensitive to
distinguish different cancer subtypes.
The next functional cluster of snoRNA is SNORD123 (rank 13), which was first reported by
Yang et al. in 2006; moreover, this C/D box snoRNA has been initially predicted and further validated
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using Northern blot [39]. Although few studies have revealed in detail the potential biological function
of SNORD123, a specific publication [40] in 2012 confirmed that this snoRNA may regulate the
hypermethylation status of functional CpG islands in specific tumor subgroups, such as colorectal
and lung cancer. Therefore, SNORD123 may be one of the significant biomarkers for the identification
of LUAD and LUSC. Similar to SNORD123, SNORD19 has also been reported to have a different
expression pattern in different tumor subtypes [41], implying its potential capacity for cancer subtyping.
The following snoRNA cluster is HBII-85-29, targeting the antisense sequence of SNURF-SNRNP-
UBE3A (transcription unit) [30,42,43]. HBII-85-29 is specifically expressed in the brain and uterus.
Thus, it may be functionally connected to LGG and uterine corpus endometrial carcinoma (UCEC).
Recent publications confirmed that HBII-85-29 might be functionally connected to the pathogenesis
of hypothalamus, further implying the potential relationship between snoRNA HBII-85-29 and
LGG [44,45]. Therefore, HBII-85-29 may also be sufficiently specific for further subgrouping of the
eight tumor subtypes.
The following identified cancer subtype-contributing snoRNA is also a C/D box snoRNA named
HBII-420. HBII-420, which targets a hypothetical protein, was also first identified and validated
by Huttenhofer in 2001 [33]. Although limited reports confirmed the contribution of HBII-420 in
tumorigenesis, two studies on lung adenocarcinoma [46] and multiple myeloma [47] confirmed that
with specific potential pathogenic expression pattern, HBII-420 might be functionally related to these
two tumor subtypes. For the eight tumor subtypes in this study, differentiating lung adenocarcinoma
from other tumor subtypes using HBII-420 is relatively effective.
Based on the expression pattern of optimal snoRNAs, we concluded that distinguishing eight
tumor subtypes by using these snoRNAs is effective and accurate, validating that snoRNAs may also
contribute to precise tumor subtyping.
3.2. Analysis of Optimal snoRNA-Based Tumor Subtyping Rules
In addition to the qualitative analysis mentioned above, based on the detailed expression level
of snoRNA provided by our reference dataset in Section 4.1 [29], we set up a series of systematic
quantitative distinctive rules for further detailed identification of each tumor subgroup among the
eight cancer types. In total, we obtained 69 rules for all eight tumor subtypes (Table S2). However, due
to the limitation of the manuscript, no space can be used to analyze each quantitative rule one by one.
Therefore, to display the whole blueprint of these rules, we screened out one typical quantitative rule
for each tumor subtype. The detailed analysis is listed below.
According to the quantitative rules listed in Table S2, the first identified tumor subtype is LGG.
In the first rule (rule1), three effective parameters, namely, SNORD123, U49B, SNORA1, and U3 have
been proposed. According to this rule, the high expression of U3 and low expression of SNORD123 and
U94B may indicate that the potential tumor is LGG. According to recent publications, SNORD123 is
downregulated in patients with glioma; this phenomenon is associated with personalized prognosis [48].
Moreover, a recent systematic analysis on LGG and high-grade glioma confirmed that U3 and U49B
may have identical expression pattern compared with this rule in LGG [49,50].
The first ten rules contribute to LGG identification. However, the eleventh rule (rule11) contributes
to LUSC identification, involving four optimal snoRNAs, including hTR, HBI-115, U83B, SNORA47, and
ACA31. The high expression of hTR and U83B, together with the low expression of HBI-115, SNORA47,
and ACA31, is unique in the snoRNA expression pattern of LUSC. According to a recent clinical study
on LUSC progression, the expression of hTR snoRNA promotes tumorigenesis, corresponding with
this rule [51]. Meanwhile, HBI-115, SNORA47 [52], and ACA31 all have unique expression patterns
in lung cancer, especially in LUSC, according to a study on the early stage of lung cancer; thus, this
result validates the unique indicating effects of these snoRNAs on cancer subtyping even at an early
stage [52,53].
Removing the LGG and LUSC interference, the next subgroup of rules to be discussed contributes
to PRAD identification. Rule22 involves four effective snoRNAs, namely, SNORA7, HBI-43, HBII-295,
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and HBII-52-32. The high expression of HBII-52-32, together with the low expression of SNORA7 and
HBII-295, refers to PRAD recognition. Although no detailed reports have confirmed that these three
snoRNAs may directly contribute to PRAD tumorigenesis, recent publications on C/D box snoRNAs
confirmed the potential relationship between snoRNAs and prostate tumorigenesis [23]. As for HBI-43,
such snoRNA has been identified to have a specific expression pattern in PRAD tumorigenesis and
related cancer subtypes [54]. Therefore, SNORA7, HBI-43, HBII-295, and HBII-52-32 may be specific
monitoring markers contributing to prostate cancer progression.
The next identified subgroup is LUAD. These rules involve multiple parameters including
HBII-52-32, mgU6-47, SNORD115, U81, and SNORD7. Among these parameters, U81 has a relatively
high expression level (≥ 451.69). According to recent publications, U81 is related to the invasion and
metastatic progression pattern in multiple tumor subtypes [55,56]. The identification of this snoRNA
as a potential parameter may reflect the high-grade malignancy of lung adenocarcinoma. In terms
of the specificity of this snoRNA combination, all these snoRNAs and their respective patterns have
been identified in LUAD; however, no previous reports are available on the distribution of snoRNA in
LUAD [46].
In addition to the above-mentioned four tumor subgroups, the next identified tumor subtype
is HNSC. We chose several rules involving SNORD116, SNORA73B, SCARNA4, and HBII-85-20,
for further analysis. These four snoRNAs are all functional tumor-associated snoRNAs according to
recent publications [47,57,58]. In terms of the tissue specificity of HNSC, a recent publication [59]
confirmed that SNORD116 is one of the potential transcriptomic signatures for HNSC identification,
corresponding to its specific expression pattern in these rules.
The next identified tumor subtype is UCEC. Tumor-associated snoRNAs, such as ACA56 [60],
HBII-336 [61], SNORD19 [41], and U19 [56,62], have been screened out using four quantitative
parameters for UCEC identification. Among these four parameters, U19 is a relatively unique
parameter with expression level higher than 119, indicating its potential role in tumor subtyping.
According to recent publications [56,62], snoRNA U19 (SNORA74), as an H/ACA box snoRNA,
contributes to the regulation of the famous AKT/mTOR signaling pathway. The expression level of
such gene has been screened out and functionally confirmed to participate in multiple tumor subtypes
including UCEC and gallbladder cancer [62].
The next predicted tumor subgroup is THCA. We chose an optimal quantitative rule involving
two optimal parameters, namely, SNORD123 and SNORD114, for the detailed analysis (see rule65).
No direct reports confirmed the specific expression patterns of these two noncoding snoRNAs in THCA.
However, a systematic study [63] on all noncoding RNAs in THCA reveals the potential expression
tendency of these two parameters in tumor tissues compared with normal controls, corresponding to
this rule and partially validating the efficacy and accuracy of our results.
The specific role of snoRNA in KIRC has been widely reported and confirmed [64,65]. According
to our rules, the tumor samples of the eight tumor subtypes that do not have corresponding expression
pattern with any of the rules we have extracted may be the kidney renal clear cell carcinoma samples.
According to the two discussion subsections presented above, some extracted optimal distinctive
snoRNAs and quantitative rules can be validated by recent publications, validating the reliability
of our results. Based on the whole blueprint of snoRNA distribution in multiple tumor subtypes as
summarized by a systematic study [29], we further screened out the distinctive core snoRNAs and
built up quantitative standards for the identification of different tumor subtypes based on the snoRNA
expression. This study does not only provide a new tool for tumor subtyping but also deepens the
understanding of the different distribution and contribution mechanisms of snoRNAs in various
tumor subtypes.
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4. Materials and Methods
4.1. Dataset
As shown in Gong et al. [29], the snoRNAs in cancers were investigated based on
miRNA-sequencing data. We downloaded snoRNA expression levels from at http://bioinfo.life.
hust.edu.cn/SNORic/download/. Originally, 31 cancer types were considered. However, many types
of cancer have a much smaller number of samples than others. To train the cancer type classifier in
a supervised way, we only kept the cancer types with sample sizes greater than 500 since trained
models cannot generalize well to the classes with a small number of training samples. Given that
breast invasive carcinoma had a much greater sample size than others, it was also not included in this
study. Finally, we obtained eight major cancer types. The sample sizes of these eight cancer types
are shown in Table 3. In total, the expression levels of 1524 snoRNAs were measured in these eight
cancer types, and were used to classify different cancer samples. Since the expression levels of many
snoRNAs were very low, we kept the 459 detectable snoRNAs with average RPKM (reads per kilobase
per million mapped reads) greater than 1 in 8 cancer types to classify different cancer samples.
Table 3. Sample sizes of eight major cancer types.
Cancer Type Name Number of Samples
HNSC Head and neck squamous cell 567
KIRC Kidney renal clear cell carcinoma 587
LGG Lower grade glioma 512
LUAD Lung adenocarcinoma 559
LUSC Lung squamous carcinoma 521
PRAD Prostate adenocarcinoma 535
THCA Thyroid carcinoma 581
UCEC Uterine corpus endometrial carcinoma 571
Total — 4433
4.2. Feature Selection
snoRNAs may be functionally associated with different cancer types. To identify highly related
snoRNAs for different cancer types, the MCFS [66] was first used to rank all available snoRNAs. Then,
IFS [67] with a support vector machine (SVM) was further applied to identify important snoRNAs
with the strong discriminative power for classifying different cancer types, those snoRNAs are further
used to produce classification rules for classifying different cancer samples.
4.2.1. MCFS
Monte Carlo feature selection (MCFS) [66] is used to rank input features based on multiple
decision trees. It constructs multiple decision tree classifiers, which are grown from bootstrap samples
that are randomly selected from the original training set and feature subsets. MCFS proceeds as
follows: it generates t feature subset with m features that are randomly selected from original M
features (m  M, i.e., m is much smaller than M). For a given feature subset, p decision trees are
grown on p bootstrap sample sets consisting of the features from this feature subset. The above
process is repeated t times. In total, t feature subsets and p · t decision trees are obtained. The relative
importance (RI) score of each feature is estimated based on the number of times a feature is involved in
growing the p · t decision trees. In this study, we used the MCFS software package downloaded from
http://www.ipipan.eu/staff/m.draminski/mcfs.html. According to the RI scores of features, a feature list
was generated in a descending order of RI scores.
In addition, the MCFS method can produce some informative features, which were the features
with the RI scores greater than a cutoff value. A permutation test and one-sided student’s t-test
were performed to determine the cutoff value of RI scores. Features with RI scores higher than
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this cutoff value were picked up as informative features, which were deemed to be most important
for classification.
For detailed description of MCFS, please refer to [66,68]. To date, MCFS is being applied to tackle
different biological problems [69–74].
4.2.2. IFS
Although the MCFS method can output informative features, a different classifier may need a
different number of informative features to yield the best performance. Thus, we used IFS [67] to
select important features according to their discriminate power for a given supervised classifier. Given
a ranked feature list with M features by MCFS, denoted as F = [ f1, f2, . . . , fM], in descending order,
IFS first constructed a series of feature subsets, in which each feature subset had one more feature
than the preceding one. f1 has only the top 1 feature in the ranked feature list, f2 has the top 1 and
top 2 features, and so on. Then, a selected supervised classifier was used to test the classification
performance on the samples consisting of features from each generated feature subset by using a
10-fold cross-validation [75–82]. Finally, we obtained a feature subset with the best performance and
called features in such set as the optimal features. Furthermore, the corresponding classifier with
features in such a set was called the optimal classifier.
4.2.3. Rule Learning
As mentioned in Section 4.2.1, the MCFS method can extract informative features. Here, we
adopted rule learning algorithms to build classification rules. Different from the supervised classifier
mentioned in Section 4.2.2, which was always a black-box method, that is, its classification procedures
were not clear and interpretable. The classification rules can provide a clear procedure of classification,
and they can give more information for understanding the expression pattern differences of snoRNAs
in different cancer types.
The procedures for generating rules proceed in two steps: (1) the Johnson Reducer algorithm [83]
was applied on informative features to pick up a subset of them, which can have similar classification
ability to using all informative features; (2) the rule learning algorithm, RIPPER algorithm [84], was
applied on reduced features to extract classification rules. A rule set obtained by RIPPER algorithm
describes an interaction between features (the left-hand side of the rule) and the target (the right-hand
side of the rule). For example, a rule is denoted as an IF–THEN relationship according to the expression
values, as follows: IF snoRNA1 ≥ 6.4 AND snoRNA2 ≥ 4.8, THEN cancer = HNSC. The above
procedures for building classification rules were also included in the MCFS software package and
we directly used them for further analysis. The RIPPER algorithm used to generate decision rules is
described briefly in [85] (see Figure 1 in [85]).
4.3. Support Vector Machine (SVM)
SVM [86] is a popular supervised classifier for both linear and nonlinear data, and it is widely
applied in many biological problems [76,87–94]. In addition, to be used for classification, SVM is
adopted for regression tasks in the recent work [95]. The basic idea of SVM is to find a hyperplane
with the maximum margin between two classes. For the nonlinear data, SVM first mapped these data
into a linear high-dimensional space using kernel trick [96]. Then, a linear function is fitted in the
high-dimensional space. SVM has a perfect solution for binary classification problems. However, many
classification problems are multiclass classification. To solve the multiclass classification problem,
a one-versus-the-rest strategy was adopted. Given a dataset with M classes, multiple binary SVM
classifiers are trained for M classes, wherein each SVM classifier was trained to separate the sample of
one class from the samples of the rest classes. Given a new sample, the one-versus-the-rest strategy
assigns the label with the highest probability score among the scores estimated from the multiple
binary SVMs.
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4.4. Performance Measurement
In this study, we first calculated the prediction accuracy of individual classes by using a 10-fold
cross-validation [75,97–102]. For each class, we calculated the individual TPR and FPR as follows:
TPR =
TP
TP+ FN
(1)
FPR =
FP
FP+ TN
(2)
where TP/TN is the number of correctly predicted positive/negative samples, and FN/FP is the number
of wrongly predicted positive/negative samples.
Only TPR and FPR cannot objectively estimate the prediction performance of a classifier; Matthew’s
correlation coefficient (MCC) [103–105] was also applied to evaluate the prediction performance. Given
N samples and C classes, the matrix X =
(
xi j
)
N×C represents the predicted classes of samples, and
xi j ∈ {0, 1} is a binary value; xi j is equals to 1 if the sample i is predicted to belong to class j; otherwise,
it is 0. The matrix Y =
(
yi j
)
N×C was defined as the true classes of N samples, where the binary variable
yi j = 1 when the sample i belongs to class j; otherwise, it is 0.
The MCC is defined as follows:
MCC =
cov(X, Y)√
cov(X, X)cov(Y, Y)
=
n∑
i=1
C∑
j=1
(xi j − x j)(yi j − y j)√
n∑
i=1
C∑
j=1
(xi j − x j)2
n∑
i=1
C∑
j=1
(yi j − y j)2
(3)
where x j and y j are the mean values of x j and y j, respectively.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/9/2185/
s1. Table S1. The features ranked by their RI values derived from the MCFS method, Table S2. Produced
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individual classes, overall accuracies, and MCCs by using different numbers of features selected by using the IFS
method and SVM classifiers.
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